This site is intended for health professionals only
Patients on vitamin K antagonist therapy (VKAs), such as warfarin, have a narrow therapeutic window and require regular international normalised ration (INR) monitoring to maintain optimal coagulation. The LumiraDx INR Test is a point of care test which measures quantitative prothrombin time (PT), reported as INR. Results are available from fresh capillary whole blood in 60-90* seconds.
Point of care INR testing provides several benefits over standard INR monitoring, including:
*Supratherapeutic INR > 4.0 test result could take 90-180 seconds References: 1. Tait, R.C., Hung, A. and Gardner, R.S. (2019). Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method. Clinical and Applied Thrombosis/Hemostasis, 25, p.107602961989042. 2. Wool, G.D. (2018). Benefits and Pitfalls of Point-of-Care Coagulation Testing for Anticoagulation Management. American Journal of Clinical Pathology, 151(1), pp.1-17. 3. Smith, M., Grace, S., Bronze, M.S. et al. (2012). Warfarin Management Using Point-of-Care Testing in a University-Based Internal Medicine Resident Clinic. The American Journal of the Medical Sciences, 344(4), pp.289–293. 4. Karlsson, T. (2016). A project to improve the management of patients on warfarin in a primary care setting through the introduction of a POC analysis. BMJ Quality Improvement Reports, 5(1), p.u211003.w4421.